Trial Profile
Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet - Randomized, Open-label, Two-way Crossover Study to Establish the Bioequivalence Between BAY 77-1931 Orally Disintegrating Tablet 500 mg and Fosrenol Chewable Tablet 500 mg Administered in Japanese Healthy Male Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Mar 2017
Price :
$35
*
At a glance
- Drugs Lanthanum carbonate (Primary) ; Lanthanum carbonate
- Indications Hyperphosphataemia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Bayer
- 10 Mar 2017 New trial record